



30 May 2025

To,

National Stock Exchange of India Limited, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India E-mail: takeover@nse.co.in Stock Code: NSE – HCG	BSE Limited, Compliance Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001, Maharashtra, India E-mail: corp.relations@bseindia.com Stock Code: BSE – 539787
---	---

Subject: Intimation under Regulation 31A(10) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”)

Stock Code: BSE – 539787, NSE – HCG

Dear Sir / Madam,

We refer to our letter to the stock exchanges dated 23 February 2025 regarding execution of the Share Purchase Agreement dated 23 February 2025 entered into by and amongst HealthCare Global Enterprises Limited (“**Company**”), Hector Asia Holdings II Pte. Ltd. (“**Purchaser 1**”), KIA EBT II Scheme 1 (“**Purchaser 1**”) (Purchaser 1 and Purchaser 2, collectively “**Purchasers**”) and Aceso Company Pte. Ltd. (“**Seller**”) (“**SPA**”).

Purchaser 1, together with persons acting in concert are undertaking an open offer to acquire up to 3,70,90,327 equity shares comprising of 26% of the expanded voting share capital of the Company (“**Open Offer**”) from the public shareholders of the Company. The intention of Seller to be reclassified from a shareholder in the ‘Promoter’ category to the ‘Public’ category has been disclosed in various disclosures relating to the Open Offer, including the public announcement dated 23 February 2025, detailed public statement dated 01 March 2025 and draft letter of offer dated 10 March 2025.

The Seller has on 30 May 2025 transferred: (i) 7,16,77,991 equity shares of the Company to Purchaser 1; and (ii) 2,50,044 equity shares of the Company to Purchaser 2 (collectively, “**Share Transfer**”).

The Seller and persons related to the Seller:

- do not hold more than 10% of the total voting rights of the Company;
- do not exercise control over the affairs of the listed entity directly or indirectly;
- do not have any special rights with respect to the listed entity through formal or informal arrangements including through any shareholder agreements;
- are not represented on the board of directors (including not having a nominee director) of the Company;
- do not act as key managerial personnel of the Company;
- are not ‘wilful defaulters’ as per the Reserve Bank of India Guidelines; and
- are not fugitive economic offenders.



The Company is compliant with Regulation 31A(3)(c) of the Listing Regulations.

In light of the foregoing, and the acquisition by Purchaser 1 of sole control over the Company, the Seller has been re-classified from promoter category to the public category and such reclassification shall be effective from 30 May 2025, being the date of actual transfer of shares from the promoter seeking reclassification to the Purchasers and the date on which the Purchaser 1 has taken sole control of the listed entity, in accordance with Explanation I to Regulation 31A(10) of the Listing Regulations.

The Seller has agreed to not take any actions or make any omissions which will result in the Seller being re-classified as promoter of the Company pursuant to Regulation 31A(4) of the Listing Regulations, post its re-classification as a public shareholder.

Kindly take the intimation on record and acknowledge receipt of the same.

Yours truly

For **Healthcare Global Enterprises Limited**

Sunu Manuel
Company Secretary and Compliance Officer